Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.

Hanke, Nina; Kunz, Claudia; Thiemann, Meinolf; Fricke, Harald; Lehr, Thorsten

Hanke, Nina; Kunz, Claudia; Thiemann, Meinolf; Fricke, Harald; Lehr, Thorsten.

Afiliación

Hanke N; Clinical Pharmacy, Saarland University, 66123 Saarbrücken, Germany. n.hanke@mx.uni-saarland.de.
Kunz C; Apogenix AG, 69120 Heidelberg, Germany. claudiakunz@gmx.de.
Thiemann M; Apogenix AG, 69120 Heidelberg, Germany. meinolf.thiemann@apogenix.com.
Fricke H; Apogenix AG, 69120 Heidelberg, Germany. harald.fricke@me.com.
Lehr T; Clinical Pharmacy, Saarland University, 66123 Saarbrücken, Germany. thorsten.lehr@mx.uni-saarland.de.

Pharmaceutics ; 11(4)2019 Apr 01.

Article en En | MEDLINE | ID: mdl-30939793

Palabras clave

pediatric PBPK; pediatric drug development; pediatric investigation plan (PIP); physiologically-based pharmacokinetic (PBPK) modeling; therapeutic proteins; translational modeling

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Pharmaceutics Año: 2019 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google